LynxCare Blog

We are proud to share that we have been recognized as one of the World's Best Digital Health Companies by Newsweek and Statista!

As Heart Failure Awareness Week comes to a close, we wanted to take a moment to reflect on the insights shared throughout the week. We've delved into various aspects of heart failure management, from the promise of AI-NLP technology to bridging the gaps in heart failure research.

LynxCare is excited to announce the appointment of Laurent van Lerberghe, former Chief Strategy Officer at Sanofi, as Investor and Board Advisor. LynxCare is a scale-up company in Clinical Artificial Intelligence part of the CB Insights Global Digital Health 150, supported by renowned VC investors MTIP (CH), Elaia (FR), B2Ventures (CH-DE) and Heran partners (BE).

We are proud to share that we have successfully renewed our ISO 27001 and NEN 7510 certifications. These certifications are not just badges, but a reflection of our commitment to maintaining the highest information security standards in healthcare!

“We are thrilled to embark on this partnership journey with Keyrus Life Science and are proud to have already set the first successful steps in France, with new geographies on our horizon,” says Georges De Feu, CEO LynxCare.

We discuss the potential of the abundant RWD for lung cancer presenting an invaluable resource when translated into RWE. While clinical trials are essential, they may not fully represent the real-world patient population. RWE complements clinical trial evidence by providing insights on treatment outcomes in broader, unselected patient groups, helping inform reimbursement decisions and ensuring access to innovative therapies.